(firstQuint)MSI-78 Topical Cream vs.

 Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers.

 Approximately 224 adults will be enrolled in an outpatient Phase III study to compare the safety and efficacy of topically applied magainin peptide (MSI-78) to that of ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic, in the treatment of infected diabetic foot ulcers.

 This is a randomized, controlled, double-blind trial that will involve twenty or more clinical centers.

.

 MSI-78 Topical Cream vs.

 Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers@highlight

224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.

